At the multivariate analysis, in the L-sided tumor group, third line regimen (anti-EGFR vs R/T) was independently associated with PFS [HR 0.45 (95% CI 0.25–0.80), p=0.006], but not with OS. The gene discussed is EGFR; the disease is neoplasm.